{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:30:46Z","timestamp":1783099846442,"version":"3.54.6"},"reference-count":31,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The utility of brentuximab vedotin (BV<\/jats:styled-content>) in CD30+<\/jats:sup> systemic lymphomas is established, however evidence for treating primary cutaneous lymphoma remains limited. This study aimed to evaluate BV<\/jats:styled-content> in treating CD30+<\/jats:sup> transformed mycosis fungoides (MF<\/jats:styled-content>) and primary cutaneous anaplastic large cell lymphoma (PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content>).<\/jats:p><\/jats:sec>Methods<\/jats:title>A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid\u2010MEDLINE<\/jats:styled-content>\u00ae<\/jats:sup> and PubMed databases. The search yielded 372 reports, and 10 publications met inclusion criteria. Sixty\u2010one patients with CD30+<\/jats:sup> transformed MF<\/jats:styled-content> and seven with PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content> were included.<\/jats:p><\/jats:sec>Results<\/jats:title>Mean age at BV<\/jats:styled-content> initiation was 60.8\u00a0years (67 \u2013 PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content>; 60.1 \u2013 MF<\/jats:styled-content>), and 4.1 therapies were attempted prior to BV<\/jats:styled-content> (3.1 \u2013 PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content>; 4.2 \u2013 MF<\/jats:styled-content>). The overall response rate was 67.7% (100% \u2013 PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content>; 63.9% \u2013 MF<\/jats:styled-content>), with 16.2% of patients experiencing complete response (100% \u2013 PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content>; 6.6% \u2013 MF<\/jats:styled-content>). Mean time to clinical response was 5.3 and 9.3\u00a0weeks for PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content> and MF<\/jats:styled-content>, respectively. Mean response duration for patients with PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content> was 7.6 and 7.8\u00a0months for MF<\/jats:styled-content>. Peripheral neuropathy (57.2%) and fatigue (35.6%) were the most commonly reported adverse effects.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>This analysis summates the current evidence regarding the use of BV<\/jats:styled-content> in treating CD30+<\/jats:sup> MF<\/jats:styled-content> and PC<\/jats:styled-content>\u2010ALCL<\/jats:styled-content>. Preliminary results indicate that BV<\/jats:styled-content> is effective for CD30+<\/jats:sup> CTCL<\/jats:styled-content>, however additional studies with larger sample sizes are necessary. The study provides clinicians with the clinical context in which BV<\/jats:styled-content> may be appropriate as well as information regarding therapeutic expectations and outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.13696","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T11:54:39Z","timestamp":1501588479000},"page":"1400-1405","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Brentuximab vedotin in CD30+<\/sup> primary cutaneous T\u2010cell lymphomas: a review and analysis of existing data"],"prefix":"10.1111","volume":"56","author":[{"given":"Tyler H.","family":"Enos","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Texas Southwestern Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Feigenbaum","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Texas Southwestern Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather W.","family":"Wickless","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Texas Southwestern Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70140-O"},{"key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30\u2010 positive lymphoproliferative disorders: long term follow\u2010up data of 219 patients and guidelines for diagnosis and treatment: a report from the Dutch Cutaneous Lymphoma Group","volume":"95","author":"Bekkenk M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.4.504"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70491-3"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11780"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1998.4636"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110608"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.775434"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.876496"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.008"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13220"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1610-3"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3787"},{"key":"e_1_2_5_22_1","first-page":"29","article-title":"Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin","volume":"6","author":"Kaffenberger BH","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1629"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.12.008"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1874"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13337"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-014-0275-7"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1515\/raon-2015-0036"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000347192"},{"key":"e_1_2_5_31_1","unstructured":"RahbarZ LiS KimJ et\u00a0al.Variability in CD30 and other biomarker expression levels in mycosis fungoides\/Sezary syndrome: challenges in tissue biomarker interpretation. 3rd World Congress of Cutaneous Lymphomas.2016: F(02)."},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2016.11.005"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.13696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.13696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:56:52Z","timestamp":1695718612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.13696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/ijd.13696"],"URL":"https:\/\/doi.org\/10.1111\/ijd.13696","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"2017-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}